Management of severe sepsis

Dashiell Gantner, Chris Mason

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Severe sepsis is a heterogenous condition affecting multiple organ systems, and is commonly encountered in the hospital setting due to both community and nosocomial infections. Although the incidence of severe sepsis has increased over the past decades, there is evidence that mortality in developed world settings has improved. Management of the septic patient involves rapid evaluation and prompt initiation of both supportive and specific therapies. Such patients commonly require admission to the intensive care unit (ICU) for invasive monitoring and haemodynamic support. Resuscitation, early initiation of broad-spectrum antimicrobial therapy and source control remain the cornerstones of therapy. Recent studies have shown no benefit to early goal-directed therapy or albumin as a resuscitation fluid, while hydroxyethyl starches have been shown to be harmful. Corticosteroids remain a controversial therapy. This review summarizes the contemporary evidence regarding diagnostic and treatment strategies of severe sepsis, with emphasis on patients in critical care settings.

Original languageEnglish
Pages (from-to)593-597
Number of pages5
JournalAnaesthesia and Intensive Care Medicine
Volume16
Issue number12
DOIs
Publication statusPublished - 1 Dec 2015

Keywords

  • Complications
  • infection
  • intensive care
  • outcomes
  • septic shock
  • severe sepsis
  • treatment

Cite this

Gantner, Dashiell ; Mason, Chris. / Management of severe sepsis. In: Anaesthesia and Intensive Care Medicine. 2015 ; Vol. 16, No. 12. pp. 593-597.
@article{6ce2a63990f14148bb86ee55aa2d1aba,
title = "Management of severe sepsis",
abstract = "Severe sepsis is a heterogenous condition affecting multiple organ systems, and is commonly encountered in the hospital setting due to both community and nosocomial infections. Although the incidence of severe sepsis has increased over the past decades, there is evidence that mortality in developed world settings has improved. Management of the septic patient involves rapid evaluation and prompt initiation of both supportive and specific therapies. Such patients commonly require admission to the intensive care unit (ICU) for invasive monitoring and haemodynamic support. Resuscitation, early initiation of broad-spectrum antimicrobial therapy and source control remain the cornerstones of therapy. Recent studies have shown no benefit to early goal-directed therapy or albumin as a resuscitation fluid, while hydroxyethyl starches have been shown to be harmful. Corticosteroids remain a controversial therapy. This review summarizes the contemporary evidence regarding diagnostic and treatment strategies of severe sepsis, with emphasis on patients in critical care settings.",
keywords = "Complications, infection, intensive care, outcomes, septic shock, severe sepsis, treatment",
author = "Dashiell Gantner and Chris Mason",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.mpaic.2015.09.012",
language = "English",
volume = "16",
pages = "593--597",
journal = "Anaesthesia and Intensive Care Medicine",
issn = "1472-0299",
publisher = "Elsevier",
number = "12",

}

Management of severe sepsis. / Gantner, Dashiell; Mason, Chris.

In: Anaesthesia and Intensive Care Medicine, Vol. 16, No. 12, 01.12.2015, p. 593-597.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Management of severe sepsis

AU - Gantner, Dashiell

AU - Mason, Chris

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Severe sepsis is a heterogenous condition affecting multiple organ systems, and is commonly encountered in the hospital setting due to both community and nosocomial infections. Although the incidence of severe sepsis has increased over the past decades, there is evidence that mortality in developed world settings has improved. Management of the septic patient involves rapid evaluation and prompt initiation of both supportive and specific therapies. Such patients commonly require admission to the intensive care unit (ICU) for invasive monitoring and haemodynamic support. Resuscitation, early initiation of broad-spectrum antimicrobial therapy and source control remain the cornerstones of therapy. Recent studies have shown no benefit to early goal-directed therapy or albumin as a resuscitation fluid, while hydroxyethyl starches have been shown to be harmful. Corticosteroids remain a controversial therapy. This review summarizes the contemporary evidence regarding diagnostic and treatment strategies of severe sepsis, with emphasis on patients in critical care settings.

AB - Severe sepsis is a heterogenous condition affecting multiple organ systems, and is commonly encountered in the hospital setting due to both community and nosocomial infections. Although the incidence of severe sepsis has increased over the past decades, there is evidence that mortality in developed world settings has improved. Management of the septic patient involves rapid evaluation and prompt initiation of both supportive and specific therapies. Such patients commonly require admission to the intensive care unit (ICU) for invasive monitoring and haemodynamic support. Resuscitation, early initiation of broad-spectrum antimicrobial therapy and source control remain the cornerstones of therapy. Recent studies have shown no benefit to early goal-directed therapy or albumin as a resuscitation fluid, while hydroxyethyl starches have been shown to be harmful. Corticosteroids remain a controversial therapy. This review summarizes the contemporary evidence regarding diagnostic and treatment strategies of severe sepsis, with emphasis on patients in critical care settings.

KW - Complications

KW - infection

KW - intensive care

KW - outcomes

KW - septic shock

KW - severe sepsis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84983203445&partnerID=8YFLogxK

U2 - 10.1016/j.mpaic.2015.09.012

DO - 10.1016/j.mpaic.2015.09.012

M3 - Review Article

VL - 16

SP - 593

EP - 597

JO - Anaesthesia and Intensive Care Medicine

JF - Anaesthesia and Intensive Care Medicine

SN - 1472-0299

IS - 12

ER -